Kyung Hae Jung

Ulsan College — South Korea

Medicine · Health Sciences

55h-index15.7kcitations449works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(123), HER2/EGFR in Cancer Research(117), Breast Cancer Treatment Studies(112), Cancer Treatment and Pharmacology(98), Colorectal Cancer Treatments and Studies(42)

Publications446 total

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study
ESMO Open·2025· 1 citedOpen Access
Data from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figures S1-11 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S1 and S4 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
2025Open Access
Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
Clinical Breast Cancer·2025
Authors’ Reply: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study
Epidemiology and Health·2025Open Access
Quality Matters: Effect of High-Quality Early Palliative Care in Advanced Cancer
Journal of Pain and Symptom Management·2025· 1 cited
508P Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Annals of Oncology·2025
LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial
Annals of Oncology·2025· 8 citedOpen Access
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Clinical Cancer Research·2025· 1 cited
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
BMC Cancer·2025Open Access
Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
The Lancet Regional Health - Western Pacific·2025Open Access
Abstract P2-05-17: The predictive and prognostic value of 18F-FES PET/CT in patients with advanced breast cancer treated with endocrine therapy with cyclin-dependent kinase 4/6 inhibitor
Clinical Cancer Research·2025
Abstract LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06
Clinical Cancer Research·2025· 2 cited
Abstract PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21)
Clinical Cancer Research·2025
Abstract P2-11-02: Is Adjuvant Chemotherapy Needed in Small Node-Negative Triple Negative Breast Cancer?
Clinical Cancer Research·2025
Abstract P4-08-01: pionERA Breast Cancer: Phase 3 study of first-line giredestrant vs fulvestrant, + a CDK4/6 inhibitor, in patients with estrogen receptor+, HER2- locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy
Clinical Cancer Research·2025
Abstract P3-11-05: Three-year efficacy and safety of neoadjuvant chemotherapy with pertuzumab, atezolizumab, docetaxel, and trastuzumab in patients with stage II/III ERBB2-positive breast cancer (NeoPATH): a nonrandomized, multi-institutional, phase 2 trial
Clinical Cancer Research·2025
page 1 of 23Next →

Frequent Co-authors

Seung‐Yong Jeong(19), Dae Yong Kim(18), Hee Jin Chang(18), Hyo Seong Choi(17), Seok‐Byung Lim(15), Yong Sang Hong(11), Dae Kyung Sohn(9), Seock‐Ah Im(9), Jee Hyun Kim(8), Tae Hyun Kim(8), Ji Won Park(7), Sun Young Kim(7), Joohyuk Sohn(5), Nadia Harbeck(5), Jae-Gahb Park(5), Duck‐Woo Kim(4), Jae Hwan Oh(4), Sara A. Hurvitz(4), Keun Seok Lee(4), Young‐Hyuck Im(4)